Prevalence of Janus Kinase 2 mutations in patients with unusual site venous thrombosis.

We aimed to study patients with splanchnic vein thrombosis (SVT) and cerebral vein thrombosis (CVT) searching for JAK2 mutations. We evaluated 14 patients (median age: 41.5 years) with portal vein thrombosis (PVT) = 7; mesenteric vein thrombosis (MVT) = 3; and CVT = 4.

Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders.

Objective: To determine the prevalence of JAK2 V617F mutation and its clinical correlation in patients with chronic myeloproliferative disorders (CMD): polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF).

Materials And Methods: Detection of JAK2 V617F mutation by allele specific-PCR.

Results: One hundred and three patients with CMD were included in the study.